TSHA Insider Trading

Insider Ownership Percentage: 2.70%
Insider Buying (Last 12 Months): $2,999,999.25
Insider Selling (Last 12 Months): $0.00

Taysha Gene Therapies Insider Trading History Chart

This chart shows the insider buying and selling history at Taysha Gene Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Taysha Gene Therapies Share Price & Price History

Current Price: $2.51
Price Change: Price Increase of +0.14 (5.91%)
As of 05/15/2025 04:52 PM ET

This chart shows the closing price history over time for TSHA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarAprMay$2.37Closing price on 05/14/25:

SEC Filings (Institutional Ownership Changes) for Taysha Gene Therapies (NASDAQ:TSHA)

77.70% of Taysha Gene Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TSHA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$4.53Mbought$262ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M$0$100MTotal InflowsTotal Outflows
Taysha Gene Therapies logo
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Read More on Taysha Gene Therapies

Today's Range

Now: $2.51
Low: $2.30
High: $2.77

50 Day Range

MA: $1.68
Low: $1.13
High: $2.58

52 Week Range

Now: $2.51
Low: $1.05
High: $4.32

Volume

6,093,346 shs

Average Volume

2,841,709 shs

Market Capitalization

$514.69 million

P/E Ratio

3.98

Dividend Yield

N/A

Beta

0.9

Who are the company insiders with the largest holdings of Taysha Gene Therapies?

Taysha Gene Therapies' top insider investors include:
  1. Paul B Manning (Major Shareholder)
  2. RA Session II (Major Shareholder)
  3. Sean P Nolan (CEO)
  4. John A Stalfort III (Director)
  5. Kamran Alam (CFO)
  6. Sukumar Nagendran (Insider)
Learn More about top insider investors at Taysha Gene Therapies.

Who are the major institutional investors of Taysha Gene Therapies?

Taysha Gene Therapies' top institutional investors include:
  1. Wellington Management Group LLP — 0.30%
  2. Charles Schwab Investment Management Inc. — 0.27%
  3. Nuveen LLC — 0.27%
  4. Kovitz Investment Group Partners LLC — 0.14%
  5. Jefferies Financial Group Inc. — 0.12%
  6. Rhumbline Advisers — 0.10%
Learn More about top institutional investors of Taysha Gene Therapies stock.

Which institutional investors are selling Taysha Gene Therapies stock?

In the last quarter, TSHA stock was sold by these institutional investors:
  1. Deutsche Bank AG

Which institutional investors are buying Taysha Gene Therapies stock?

During the previous quarter, TSHA stock was bought by institutional investors including:
  1. Nuveen LLC
  2. Kovitz Investment Group Partners LLC
  3. Jefferies Financial Group Inc.
  4. XTX Topco Ltd
  5. BIT Capital GmbH
  6. Y Intercept Hong Kong Ltd
  7. EntryPoint Capital LLC
  8. Charles Schwab Investment Management Inc.
During the previous year, these company insiders have bought Taysha Gene Therapies stock:
  1. Paul B Manning (Major Shareholder)
  2. RA Session II (Major Shareholder)
  3. Sean P Nolan (CEO)
  4. John A Stalfort III (Director)
Learn More investors buying Taysha Gene Therapies stock.